NOK 1.9
(-5.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 41.69 Million NOK | 3.15% |
2022 | 40.42 Million NOK | 93.22% |
2021 | 20.92 Million NOK | -28.5% |
2020 | 29.26 Million NOK | 57.56% |
2019 | 18.57 Million NOK | -21.03% |
2018 | 23.51 Million NOK | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q3 | - NOK | -100.0% |
2023 Q1 | - NOK | -100.0% |
2023 Q4 | 41.69 Million NOK | 0.0% |
2023 FY | 41.69 Million NOK | 3.15% |
2023 Q2 | 38.1 Million NOK | 0.0% |
2022 FY | 40.42 Million NOK | 93.22% |
2022 Q4 | 40.42 Million NOK | 0.0% |
2022 Q2 | 21.56 Million NOK | 0.0% |
2021 Q2 | 20.45 Million NOK | 0.0% |
2021 FY | 20.92 Million NOK | -28.5% |
2021 Q4 | 20.92 Million NOK | 0.0% |
2020 FY | 29.26 Million NOK | 57.56% |
2020 Q4 | 29.26 Million NOK | 0.0% |
2019 FY | 18.57 Million NOK | -21.03% |
2018 FY | 23.51 Million NOK | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aqua Bio Technology ASA | 15.72 Million NOK | -165.179% |
ArcticZymes Technologies ASA | 30.02 Million NOK | -38.861% |
BerGenBio ASA | 46.85 Million NOK | 11.022% |
Hofseth BioCare ASA | 348.97 Million NOK | 88.052% |
PCI Biotech Holding ASA | 5 Million NOK | -732.555% |
Thor Medical ASA | 58.91 Million NOK | 29.224% |
Ultimovacs ASA | 69.64 Million NOK | 40.136% |